Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate.
The effects of priming with a group B Streptococcus type III capsular polysaccharide (GBS CPS III)-recombinant cholera toxin B subunit (rCTB) conjugate, purified GBS CPS III or rCTB alone on the systemic and mucosal immune responses to CPS III after intranasal (i.n.) immunization were investigated in mice. Priming with purified GBS CPS III followed by boosting with GBS CPS III-rCTB conjugate or priming with the conjugate followed by boosting with free CPS induced comparable levels of specific IgG and IgA in both serum and in lungs and vagina. However, i.n. immunization comprising both priming and boosting with conjugate was superior to priming with CPS and boosting with conjugate or the reverse, especially with regard to inducing mucosal IgA anti-CPS responses. All the immunization schemes, except priming and boosting with free CPS, induced high and similar levels of IgG1 in serum. In contrast, mice primed with free CPS III and then boosted with CPS III-rCTB conjugate by the i.n. route failed to produce significant levels of IgG2a, IgG2b and IgG3 in serum, at difference from mice primed with the conjugate and boosted with either conjugate or free CPS. Pre-immunization with rCTB either i.n. or i.p. did not suppress specific serum IgG responses induced by GBS CPS III-rCTB conjugate intranasally, but did inhibit serum and especially mucosal IgA responses. Our findings suggest that priming with CPS affects the distribution of IgG subclasses to GBS CPS and that pre-existing anti-carrier rCTB immunity can have an inhibitory effect on mucosal immune responses elicited by the conjugate vaccine given by the i.n. route.
Shen
X
X
Department of Medical Microbiology and Immunology, Göteborg University, Guldhedsgatan 10, SE-413 46, Gothenburg, Sweden.
Lagergård
T
T
Yang
Y
Y
Lindblad
M
M
Fredriksson
M
M
Wallerström
G
G
Holmgren
J
J
D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D002772:Cholera Toxin / Q000008:administration & dosage*; D005260:Female; D018928:Immunity, Mucosal; D007117:Immunization, Secondary; D007074:Immunoglobulin G / Q000097:blood / Q000145:classification; D008168:Lung / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage*; D022541:Streptococcal Vaccines / Q000008:administration & dosage*; D013292:Streptococcus agalactiae / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage; D014614:Vaccines, Synthetic / Q000008:administration & dosage; D014621:Vagina / Q000276:immunology
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D011135:Polysaccharides, Bacterial; D022541:Streptococcal Vaccines; D018074:Vaccines, Conjugate; D014614:Vaccines, Synthetic; C032263:streptococcal polysaccharide type III group B; D002772:Cholera Toxin